TSE:CPH

Cipher Pharmaceuticals Competitors

C$1.33
-0.02 (-1.48 %)
(As of 04/15/2021 09:40 AM ET)
Add
Compare
Today's Range
C$1.32
Now: C$1.33
C$1.35
50-Day Range
C$0.87
MA: C$1.10
C$1.45
52-Week Range
C$0.70
Now: C$1.33
C$1.55
Volume882 shs
Average Volume87,698 shs
Market CapitalizationC$35.87 million
P/E Ratio6.36
Dividend YieldN/A
BetaN/A

Competitors

Cipher Pharmaceuticals (TSE:CPH) Vs. WMD, ASP, NINE, FLWR, RX, and MDP

Should you be buying CPH stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Cipher Pharmaceuticals, including WeedMD (WMD), Acerus Pharmaceuticals (ASP), Delta 9 Cannabis (NINE), The Flowr (FLWR), BioSyent (RX), and Medexus Pharmaceuticals (MDP).

Cipher Pharmaceuticals (TSE:CPH) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Earnings & Valuation

This table compares Cipher Pharmaceuticals and WeedMD's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$21.61 million1.66C$5.64 millionC$0.216.36
WeedMDC$27.21 million2.81C$-21,702,912.00C($0.09)-3.52

Cipher Pharmaceuticals has higher earnings, but lower revenue than WeedMD. WeedMD is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and WeedMD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
WeedMDN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Cipher Pharmaceuticals and WeedMD, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01102.50
WeedMD02002.00

WeedMD has a consensus target price of C$0.58, suggesting a potential upside of 85.19%. Given WeedMD's higher possible upside, analysts plainly believe WeedMD is more favorable than Cipher Pharmaceuticals.

Summary

Cipher Pharmaceuticals beats WeedMD on 5 of the 8 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and Acerus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$21.61 million1.66C$5.64 millionC$0.216.36
Acerus PharmaceuticalsC$1.09 million77.94C$-58,428,344.00C($0.04)-1.45

Cipher Pharmaceuticals has higher revenue and earnings than Acerus Pharmaceuticals. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
Acerus PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and Acerus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01102.50
Acerus Pharmaceuticals0000N/A

Summary

Cipher Pharmaceuticals beats Acerus Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and Delta 9 Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$21.61 million1.66C$5.64 millionC$0.216.36
Delta 9 CannabisC$12.87 million6.94C$4.69 millionC$0.0519.07

Cipher Pharmaceuticals has higher revenue and earnings than Delta 9 Cannabis. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and Delta 9 Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01102.50
Delta 9 Cannabis0000N/A

Summary

Cipher Pharmaceuticals beats Delta 9 Cannabis on 4 of the 6 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and The Flowr (CVE:FLWR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and The Flowr's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$21.61 million1.66C$5.64 millionC$0.216.36
The FlowrC$5.96 million18.50C$-141,450,897.00C($0.39)-0.78

Cipher Pharmaceuticals has higher revenue and earnings than The Flowr. The Flowr is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and The Flowr's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
The FlowrN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and The Flowr, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01102.50
The Flowr0000N/A

The Flowr has a consensus target price of C$0.70, suggesting a potential upside of 122.22%. Given The Flowr's higher probable upside, analysts clearly believe The Flowr is more favorable than Cipher Pharmaceuticals.

Summary

Cipher Pharmaceuticals beats The Flowr on 5 of the 7 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and BioSyent's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$21.61 million1.66C$5.64 millionC$0.216.36
BioSyentC$22.33 million4.31C$3.69 millionC$0.2926.07

Cipher Pharmaceuticals has higher earnings, but lower revenue than BioSyent. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
BioSyentN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and BioSyent, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01102.50
BioSyent02002.00

BioSyent has a consensus target price of C$7.00, suggesting a potential downside of 11.39%. Given BioSyent's higher probable upside, analysts clearly believe BioSyent is more favorable than Cipher Pharmaceuticals.

Summary

BioSyent beats Cipher Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$21.61 million1.66C$5.64 millionC$0.216.36
Medexus PharmaceuticalsC$108.29 million1.29C$-34,573,801.00C($1.81)-4.03

Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
Medexus PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and Medexus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals01102.50
Medexus Pharmaceuticals00203.00

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.


Cipher Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WMD
WeedMD
1.3$0.31-1.6%C$95.35 millionC$27.21 million-3.52
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.06-9.1%C$92.26 millionC$1.09 million-1.45Gap Up
NINE
Delta 9 Cannabis
0.8$1.03-2.9%C$89.36 millionC$12.87 million19.07Gap Down
FLWR
The Flowr
1.0$0.31-3.3%C$70.01 millionC$5.96 million-0.78
RX
BioSyent
0.8$7.56-0.5%C$64.81 millionC$22.33 million26.07News Coverage
MDP
Medexus Pharmaceuticals
0.6$7.30-0.7%C$38.66 millionC$108.29 million-4.03
VIR
Viridium Pacific Group
0.7$0.38-5.3%C$37.54 millionC$1.09 million-2.97Gap Down
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29-7.0%C$36.73 millionN/A-2.61News Coverage
Gap Up
IN
InMed Pharmaceuticals
0.6$3.95-3.8%C$32.37 millionN/A-2.18Gap Down
NDVA
Indiva
1.3$0.45-2.2%C$27.54 millionC$7.92 million-3.52Gap Up
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.11-4.5%C$21.51 millionC$8.50 million-0.31
EVE
Eve & Co Incorporated
1.0$0.36-2.8%C$21.32 millionC$2.84 million-1.12Gap Down
SUGR
SugarBud Craft Growers
0.7$0.06-9.1%C$11.81 millionC$66,906.00-0.03News Coverage
Gap Down
NU
NeutriSci International
0.5$0.19-2.6%C$8.65 millionC$69,626.00-14.62Gap Up
AQS
Aequus Pharmaceuticals
0.9$0.22-2.3%C$6.03 millionC$2.28 million-10.00Gap Up
LBL
Lattice Biologics
0.5$0.05-11.1%C$4.67 millionC$2.24 million-2.37Gap Up
THCX
(THCX.V)
0.6$5.30-6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Down
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Down
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Down
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Down
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.